Please assess the completion status of the following clinical trial:

Trial Title: Phase III Confirmatory Study in Erythropoietic Protoporphyria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects with characteristic symptoms of EPP phototoxicity and a biochemically-confirmed diagnosis of EPP.~* Aged 18 years old and above (inclusive).~* Able to understand and sign the written Informed Consent Form.~* Willing to take precautions to prevent pregnancy until completion of the study (Day 180).~Exclusion Criteria:~* Any allergy to afamelanotide or the polymer contained in the implant or to lidocaine or other local anesthetic to be used during the administration of the study medication~* EPP patients with significant hepatic involvement~* Personal history of melanoma or dysplastic nevus syndrome.~* Current Bowen's disease, basal cell carcinoma, squamous cell carcinoma, or other malignant or premalignant skin lesions.~* Any other photodermatosis such as polymorphic light eruption, actinic prurigo, discoid lupus erythematosus, chronic actinic dermatitis or solar urticaria.~* Any evidence of clinically significant organ dysfunction or any clinically significant deviation from normal in the clinical or laboratory determinations.~* Acute history of drug or alcohol abuse (in the last 6 months).~* Patient assessed as not suitable for the study in the opinion of the Investigator (e.g. noncompliance history, allergic to local anesthetics, faints when given injections or giving blood).~* Participation in a clinical trial for an investigational agent within 30 days prior to the screening visit.~* Prior and concomitant therapy with medications which may interfere with the objectives of the study, including drugs that cause photosensitivity or skin pigmentation.~* Female who is pregnant (confirmed by positive serum β-HCG pregnancy test prior to baseline) or lactating.~* Females of child-bearing potential (pre-menopausal, not surgically sterile) not using adequate contraceptive measures (i.e. oral contraceptives, diaphragm plus spermicide, intrauterine device).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Afamelanotide (Type: EXPERIMENTAL): One 16mg subcutaneous implant every 2 months for 6 months.
- Placebo (Type: PLACEBO_COMPARATOR): One placebo subcutaneous implant every 2 months for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).